Literature DB >> 33177182

MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates.

Juliette Hordeaux1, Elizabeth L Buza1, Brianne Jeffrey1, Chunjuan Song1, Tahsin Jahan1, Yuan Yuan1, Yanqing Zhu1, Peter Bell1, Mingyao Li1, Jessica A Chichester1, Roberto Calcedo1, James M Wilson2.   

Abstract

Delivering adeno-associated virus (AAV) vectors into the central nervous system of nonhuman primates (NHPs) via the blood or cerebral spinal fluid is associated with dorsal root ganglion (DRG) toxicity. Conventional immune-suppression regimens do not prevent this toxicity, possibly because it may be caused by high transduction rates, which can, in turn, cause cellular stress due to an overabundance of the transgene product in target cells. To test this hypothesis and develop an approach to eliminate DRG toxicity, we exploited endogenous expression of microRNA (miR) 183 complex, which is largely restricted to DRG neurons, to specifically down-regulate transgene expression in these cells. We introduced sequence targets for miR183 into the vector genome within the 3' untranslated region of the corresponding transgene messenger RNA and injected vectors into the cisterna magna of NHPs. Administration of unmodified AAV vectors resulted in robust transduction of target tissues and toxicity in DRG neurons. Consistent with the proposal that immune system activity does not mediate this neuronal toxicity, we found that steroid administration was ineffective in alleviating this pathology. However, including miR183 targets in the vectors reduced transgene expression in, and toxicity of, DRG neurons without affecting transduction elsewhere in the primate's brain. This approach might be useful in reducing DRG toxicity and the associated morbidity and should facilitate the development of AAV-based gene therapies for many central nervous system diseases.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33177182     DOI: 10.1126/scitranslmed.aba9188

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  29 in total

1.  AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset.

Authors:  David Goertsen; Nicholas C Flytzanis; Nick Goeden; Miguel R Chuapoco; Alexander Cummins; Yijing Chen; Yingying Fan; Qiangge Zhang; Jitendra Sharma; Yangyang Duan; Liping Wang; Guoping Feng; Yu Chen; Nancy Y Ip; James Pickel; Viviana Gradinaru
Journal:  Nat Neurosci       Date:  2021-12-09       Impact factor: 24.884

Review 2.  Hemophilia gene therapy: ushering in a new treatment paradigm?

Authors:  Lindsey A George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Eliminating Panglossian thinking in development of AAV therapeutics.

Authors:  Radoslaw Kaczmarek; Glenn F Pierce; Declan Noone; Brian O'Mahony; David Page; Mark W Skinner
Journal:  Mol Ther       Date:  2021-11-10       Impact factor: 11.454

Review 4.  Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary.

Authors:  Jill A Morris; Chris H Boshoff; Nina F Schor; Ling M Wong; Guangping Gao; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-09-20       Impact factor: 11.454

5.  Rescue of a familial dysautonomia mouse model by AAV9-Exon-specific U1 snRNA.

Authors:  Giulia Romano; Federico Riccardi; Erica Bussani; Simone Vodret; Danilo Licastro; Isabella Ragone; Giuseppe Ronzitti; Elisabetta Morini; Susan A Slaugenhaupt; Franco Pagani
Journal:  Am J Hum Genet       Date:  2022-07-28       Impact factor: 11.043

6.  A Cautiously Optimistic Outlook of a Designer Therapy for 1% of Duchenne Muscular Dystrophy Patients.

Authors:  Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2021-09       Impact factor: 4.793

Review 7.  Gene therapy for ALS: A review.

Authors:  Defne A Amado; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

Review 8.  Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.

Authors:  Julia Fakhiri; Dirk Grimm
Journal:  Mol Ther       Date:  2021-04-05       Impact factor: 11.454

9.  Assuring long-term safety of highly effective gene-modulating therapeutics for rare diseases.

Authors:  Thomas O Crawford; Charlotte J Sumner
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

10.  The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration.

Authors:  Adam Beharry; Yi Gong; James C Kim; Killian S Hanlon; Josette Nammour; Kate Hieber; Florian Eichler; Ming Cheng; Anat Stemmer-Rachamimov; Konstantina M Stankovic; Duane Bradley Welling; Carrie Ng; Casey A Maguire
Journal:  Hum Gene Ther       Date:  2021-08-26       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.